Локальныежировые депо как фактор риска сердечно-сосудистых заболеваний
Аннотация
Ожирение ассоциируется с риском развития сердечно-сосудистой патологии. Одним из механизмов, ведущих к сердечно-сосудистым осложнениям является гормональная активность локальных жировых депо. Белая жировая ткань, расположенная в эпикардиальной, висцеральной, паранефральной и периваскулярной областях, оказывает не только локальное механическое воздействие на рядом расположенные органы, но и системное действие через биологически активные вещества. Проатерогенные и провоспалительные хемокины и цитокины вызывают хроническое воспаление сосудистой стенки, пролиферацию и миграцию гладкомышечных клеток, трансформацию моноцитов в макрофаги, что ведет к дисфункции эндотелия, формированию атеросклеротической бляшки и прогрессированию атеросклероза.
Об авторах
Г. А. Чумакова
Алтайский государственный медицинский университет
Россия
Россия
Н. Г. Веселовская
Научно-исследовательский институт Комплексных проблем сердечно-сосудистых заболеваний Сибирского отделения РАМН
Россия
Россия
А. А. Козаренко
Научно-исследовательский институт Комплексных проблем сердечно-сосудистых заболеваний Сибирского отделения РАМН
Россия
Россия
Л. С. Барбараш
Алтайский краевой кардиологический диспансер
Россия
Россия
Список литературы
1. Adams K.F., Schatzkin A., Harris T.B. et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old // N. Engl. J. Med. - 2006. - Vol. 355, № 8. - P. 763-778.
2.
3. The challenge of obesity in the WHO European Region // World Health Organization, Copenhagen, Bucharest 12. - 2005.
4.
5. Narayan K.M., Boyle J.P., Geiss L.S. et al. Impact of recent increase in incidence on future diabetes burden: U.S. 2005-2050 // Diabetes Care. - 2006. - Vol. 29, № 9. - P. 2114-2116.
6.
7. Kopelman P.G. Obesity as a medical problem // Nature. - 2000. - Vol. 404, № 6778. - P. 635-643.
8.
9. Bray G.A. Medical consequences of obesity // J. Clin. Endocrinol. Metab. - 2004. - Vol. 89, № 6. - P. 2583-2589.
10.
11. Sharma A.M. Obesity and cardiovascular risk // Growth Horm. IGF Res. - 2003. - Vol. 13 (Suppl A) - P. 10-17.
12.
13. Arcaro G., Zamboni M., Rossi L. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity // Int. J. Obes. Relat. Metab. Disord. - 1999. - Vol. 23, № 9. - P. 936-942.
14.
15. Nieto F.J., Young T.B., Lind B.K. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study // J. Am. Med. Assoc. - 2000. - Vol. 283, № 14. - P. 1829-1836.
16.
17. Jacobson B.C., Somers S.C., Fuchs C.S. Body-mass index and symptoms of gastroesophageal reflux in women //N. Engl. J. Med. - 2006. - Vol. 354, № 22. - P. 2340-2348.
18.
19. Soderberg S., Ahren B., Jansson J.H. et al. Leptin is associated with increased risk of myocardial infarction // J. Intern. Med. - 1999. - Vol. 246, № 4. - P. 409-418.
20.
21. Schnabel R., Messow C.M., Lubos E., et al. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study // Eur. Heart J. - 2008. - Vol. 29, № 5. - P. 649-657.
22.
23. Rothenbacher D., Brenner H., März W. et al. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers // Eur. Heart J. - 2005. - Vol. 26, № 16. - P. 1640-1646.
24.
25. Koenig W., Khuseyinova N., Baumert J. et al. Serum Concentrations of Adiponectin and Risk of Type 2 Diabetes Mellitus and Coronary Heart Disease in Apparently Healthy Middle-Aged Men // J. Am. Coll. Cardiol. - 2006. - Vol. 48, № 7. - P. 1369-1377.
26.
27. Wallace A.M., McMahon A.D., Packard C.J. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS) // Circulation. - 2001. - Vol. 104, № 25. - P. 3052-3056.
28.
29. Juge-Aubry C.E., Henrichot E., Meier C.A. Adipose tissue: a regulator of inflammation // Best Pract. Res. Clin. Endocrinol. Metab. - 2005. - Vol. 19, № 4. - P. 547-566.
30.
31. Brook R.D. Obesity, weight loss, and vascular function // Endocrine. - 2006. - Vol. 29, № 1. - P. 21-25.
32.
33. Montani J.P., Carroll J.F., Dwyer T.M. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases // Int. J. Obes. Relat. Metab. Disord. - 2004. - Vol. 28 (Suppl. 4). - P. 58-65.
34.
35. Douketis J.D., Sharma A.M. Obesity and cardiovascular disease: pathogenic mechanisms and potential benefits of weight reduction // Semin. Vasc. Med. - 2005. - Vol. 5, № 1. - P. 25-33.
36.
37. Despres J.P. Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease // J. Endocrinol. Invest. - 2006. - Vol. 29, № 3. - P. 77-82.
38.
39. Grundy S.M., Brewer H.B. Jr., Cleeman J.I. et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition // Circulation. - 2004. - Vol. 109, № 3. - P. 433-438.
40.
41. Iacobellis G., Ribaudo M.C., Assael F. et al. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk // J. Clin. Endocrinol. Metab. - 2003. - Vol. 88, № 11. - P. 5163-5168.
42.
43. Denton R.M., Randle P.J. Concentrations of glycerides and phospholipids in rat heart and gastrocnemius muscles. Effects of alloxan-diabetes and perfusion // Biochem. J. - 1967. - Vol. 104, № 2. - P. 416-422.
44.
45. Pan D.A., Lillioja S., Kriketos A.D. et al. Skeletal muscle triglyceride levels are inversely related to insulin action // Diabetes. - 1997. - Vol. 46, № 6. - P. 983-988.
46.
47. Goodpaster B.H., Theriault R., Watkins S.C. et al. Intramuscular lipid content is increased in obesity and decreased by weight loss // Metabolism. - 2000. - Vol. 49, № 4. - P. 467-472.
48.
49. Dwyer T.M., Mizelle H.L., Cockrell K. Renal sinus lipomatosis and body composition in hypertensive, obese rabbits // Int. J. Obes. Relat. Metab. Disord. - 1995. - Vol. 19, № 12. - P. 869-874.
50.
51. Hall J.E. Mechanisms of abnormal renal sodium handling in obesity hypertension // Am. J. Hypertens. - 1997. - Vol. 10, № 5. - P. 49-55.
52.
53. Baker A.R., Silva N.F., Quinn D.W. et al. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease // Cardiovasc. Diabetol. - 2006. - Vol. 5, № 1. - P. 1-6.
54.
55. Iacobellis G., Assael F., Ribaudo M.C., Zappaterreno A. et al. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction // Obes. Res. - 2003. - Vol. 11, № 2. - P. 304-310.
56.
57. Natale F., Tedesco M., Mocerino R. Visceral adiposity and arterial stiffness: echocardiographic epicardial fat thickness reflects, better than waist circumference, carotid arterial stiffness in a large population of hypertensives // Eur. J. Echocardiography. - 2009. - Vol.10, № 4. - P. 549-555.
58.
59. Iacobellis G., Leonetti F. Epicardial adipose tissue and insulin resistance in obese subjects // J. Clin. Endocrinol. Metab. - 2005. - Vol. 90, № 11. - P. 6300-6302.
60.
61. Iacobellis G., Gao Y.J., Sharma A.M. Do cardiac and perivascular adipose tissue play a role in atherosclerosis? // Curr. Diab. Rep. - 2008. - Vol. 8, № 1. - P. 20-24.
62.
63. Mazurek T., Zhang L., Zalewski A. et al. Human epicardial adipose tissue is a source of inflammatory mediators // Circulation. - 2003. - Vol. 108, № 20. - P. 2460-2466.
64.
65. Kremen J., Dolinkova M., Krajickova J. et al. Increased subcutaneous and epicardial adipose tissue production of proinflammatory cytokines in cardiac surgery patients: possible role in postoperative insulin resistance // J. Clin. Endocrinol. Metab. - 2006. - Vol. 91, № 11. - P. 4620-4627.
66.
67. Hug C., Lodish H.F. The role of the adipocyte hormone adiponectin in cardiovascular disease // Curr. Opin. Pharmacol. - 2005. - Vol. 5, № 2. -P. 129-134.
68.
69. Silaghi A <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Silaghi%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract>., Piercecchi-Marti M.D <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Piercecchi-Marti%20MD%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract>., Grino M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Grino%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract>. Epicardial adipose tissue extent: relationship with age, body fat distribution, and coronaropathy // Obesity <javascript:AL_get(this,%20'jour',%20'Obesity%20(Silver%20Spring).');>. - 2008. - Vol. 16, № 11. - P. 2424-2430.
70.
71. Clément K., Basdevant A., Dutour A. Weight of Pericardial Fat on Coronaropathy // Arterioscler. Thromb. Vasc. Biol. - 2009. - Vol. 29, № 5. - P. 615-618.
72.
73. Ding J., Hsu F., Harris T. The association of pericardial fat with incident coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA) // Am. J. Clin. Nutr. - 2009. - Vol. 90, № 3. - P. 499-504.
74.
75. Lohn M., Dubrovska G., Lauterbach B. Periadventitial fat releases a vascular relaxing factor // FASEB J. - 2002. - Vol. 16, № 9. - P. 1057-1063.
76.
77. Verlohren S., Dubrovska G., Tsang S.Y. et al. Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries // Hypertension. - 2004. - Vol. 44, № 3. - P. 271-276.
78.
79. Henrichot E., Juge-Aubry C.E., Pernin A. et al. Production of chemokines by perivascular adipose tissue: a role in the pathogenesis of atherosclerosis? // Arterioscler. Thromb. Vasc. Biol. - 2005. - Vol. 25, № 12. - P. 2594-2599.
80.
81. Wildman R.P., Farhat G.N., Patel A.S. et al. Weight change is associated with change in arterial stiffness among healthy young adults // Hypertension. - 2005. - Vol. 45, № 2. - P. 187-192.
82.
83. Gao Y.J., Takemori K., Su L.Y. et al. Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion // Cardiovasc. Res. - 2006. - Vol. 71, № 2. - P. 363-373.
84.
85. Schaffler A., Muller-Ladner U., Scholmerich J. et al. Role of adipose tissue as an inflammatory organ in human diseases // Endocr. Rev. - 2006. - Vol. 27, № 5. - P. 449-467.
86.
87. Herrmann J., Lerman L.O., Mukhopadhyay D. et al. Angiogenesis in atherogenesis // Arterioscler. Thromb. Vasc. Biol. - 2006. - Vol. 26, № 9. - P. 1948-1957.
88.
89. Gerszten R.E., Mach F., Sauty A. et al. Chemokines, leukocytes, and atherosclerosis // J. Lab. Clin. Med. - 2000. - Vol. 136, № 2. - P. 87-92.
90.
91. Yudkin J.S., Eringa E., Stehouwer C.D. «Vasocrine» signaling from perivascular fat: a mechanism linking insulin resistance to vascular disease // Lancet. - 2005. -Vol. 365, №9 473. - P. 1817-1820.
92.
93. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance // Science. - 1993. - Vol. 259, № 5091. - P. 87-91.
94.
95. Scherrer U., Sartori C. Defective nitric oxide synthesis: a link between metabolic insulin resistance, sympathetic over activity and cardiovascular morbidity // Eur. J. Endocrinol. - 2000. - Vol. 142, № 4. - P. 315-323.
96.
97. Hausman D.B., DiGirolamo M., Bartness T.J. et al. The biology of white adipocyte proliferation // Obes. Rev. - 2001. -Vol. 2, № 4. - P. 239-254.
98.
99. Trayhurn P., Beattie J.H. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ // Proc. Nutr. Soc. - 2001. - Vol. 60, № 3. - P. 329-339.
100.
101. Suzawa M., Takada I., Yanagisawa J. et al. Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade // Nat. Cell. Biol. - 2003. - Vol. 5, № 3. - P. 224-230.
102.
103. Ronti T., Lupattelli G., Mannarino E. The endocrine function of adipose tissue: an update // Clin. Endocrinol. (Oxf). - 2006. - Vol. 64, № 4. - P. 355-365.
104.
105. Wallenius V., Wallenius K., Ahren B. et al. Interleukin-6-deficient mice develop mature-onset obesity // Nat. Med. - 2002. - Vol. 8, № 1. - P. 75-79.
106.
107. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation // N. Engl. J. Med. - 1998. - Vol. 338, № 7. - P. 436-445.
108.
109. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy // Curr. Pharm. Des. -2005. - Vol.11, № 18. - P. 2279-2299.
110.
111. Boisvert W.A. Modulation of atherogenesis by chemokines // Trends Cardiovasc. Med. - 2004. - Vol. 14, № 4. - P. 161-165.
112.
113. van Royen N., Hoefer I., Buschmann I. et al. Effects of local MCP-1 protein therapy on the development of the collateral circulation and atherosclerosis in Watanabe hyperlipidemic rabbits // Cardiovasc. Res. - 2003. - Vol. 57, № 1. - P. 178-185.
114.
115. Boring L., Gosling J., Cleary M. et al. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis // Nature. - 1998. - Vol. 394, № 6696. - P. 894-897.
116.
117. Gerhardt C.C., Romero I.A., Cancello R. et al. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes // Mol. Cell. Endocrinol. - 2001. - Vol. 175, № 1. - P. 81-92.
118.
119. Huo Y., Weber C., Forlow S.B. et al. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium // J. Clin. Inves. - 2001. - Vol. 108, № 9. - P. 1307-1314.
120.
121. Boisvert W.A., Santiago R., Curtiss L.K. at al. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice // J. Clin. Invest. - 1998. - Vol. 101, № 2. - P. 353-363.
122.
123. Straczkowski M., Dzienis-Straczkowska S., Stepien A. et al. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system // J. Clin. Endocrinol. Metab. - 2002. -Vol. 87, № 10. - P. 4602-4606.
124.
125. Luster A.D., Oppenheim J.J., Feldmann M. Cytokine reference. - London: New York, 2000. - P. 1103-1109.
126.
127. Boger C.A., Fischereder M., Deinzer M. et al. RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients // Atherosclerosis. - 2005. - Vol. 183, № 1. - P. 121-129.
128.
129. Veillard N.R., Kwak B., Pelli G. et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice // Circ. Res. - 2004. - Vol. 94, № 2. - P. 253-261.
130.
131. Miczke A., Bryl W., Szulinska M. et al. The role of adiponectin in pathogenesis of insulin resistance and metabolic syndrome // Pol. Merkur. Lekarski. - 2005. - Vol. 19, № 113. - P. 723-726.
132.
133. Kadowaki T., Yamauchi T., Kubota N. et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome // J. Clin. Invest. - 2006. - Vol. 116, № 7. - P. 1784-1792.
134.
135. Yamauchi T., Kamon J., Waki H. et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis // J. Biol. Chem. - 2003. - Vol. 278, № 4. - P. 2461-2468.
136.
137. Chandran M., Phillips S.A., Ciaraldi T. et al. Adiponectin: more than just another fat cell hormone? // Diabetes Care. - 2003. - Vol. 26, № 8. - P. 2442-2450.
138.
139. Kumada M., Kihara S., Ouchi N. et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages // Circulation. - 2004. - Vol. 109, № 17. - P. 2046-2049.
140.
141. Lau D.C., Dhillon B., Yan H. et al. Adipokines: molecular links between obesity and atheroslcerosis // Am. J. Physiol. Heart Circ. Physiol. - 2005. - Vol. 288, № 5. - P. 2031-2041.
142.
143. Kumada M., Kihara S., Sumitsuji S. et al. Coronary artery disease Association of hypoadiponectinemia with coronary artery disease in men // Arterioscler. Thromb. Vasc. Biol. - 2003. - Vol. 23, № 1. - P. 85-89.
144.
145. Pischon T., Girman C.J., Hotamisligil G.S. et al. Plasma adiponectin levels and risk of myocardial infarction in men // J. Am. Med. Assoc. - 2004. - Vol. 291, № 14. - P. 1730-1737.
146.
147. Maahs D.M., Ogden L.G., Kinney G.L. et al. Low plasma adiponectin levels predict progression of coronary artery calcification // Circulation. - 2005. - Vol. 111, № 6. - P. 747-753.
148.
149. Azuma K., Katsukawa F., Oguchi S. et al. Correlation between serum resistin level and adiposity in obese individuals // Obes. Res. - 2003. - Vol. 11, № 8. - P. 997-1001.
150.
151. Skilton M.R., Nakhla S., Sieveking D.P. et al. Pathophysiological levels of the obesity related peptides resistin and ghrelin increase adhesion molecule expression on human vascular endothelial cells // Clin. Exp. Pharmacol. Physiol. - 2005. - Vol. 32, № 10. - P. 839-844.
152.
153. Hug C., Lodish H.F. Visfatin: a new adipokine // Science. - 2005. - Vol. 307, № 5708. - P. 366-367.
154.
155. Fukuhara A., Matsuda M., Nishizawa M. et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin // Science. - 2005. - Vol. 307, № 5708. - P. 426-430.
156.
157. Cho Y.M., Youn B.S., Lee H. et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes // Diabetes Care. - 2006. - Vol. 29, № 11. - P. 2457-2461.
158.
159. Graham T.E., Yang Q., Bluher M. et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects // N. Engl. J. Med. - 2006. -Vol. 354, № 24. - P. 2552-2563.
160.
161. Juge-Aubry C.E., Meier C.A. Immunomodulatory actions of leptin // Mol. Cell. Endocrinol. - 2002. - Vol. 194, № 1. - P. 1-7.
162.
163. Chen K., Li F., Li J. Induction of leptin resistance through direct interaction of C-reactive protein with leptin // Nat. Med. - 2006. - Vol. 12, № 4. - P. 425-432.
164.
165. Correia ML, Haynes WG. Leptin, obesity and cardiovascular disease // Curr. Opin. Nephrol. Hypertens. - 2004. - Vol. 13, № 2. -P. 215-223.
166.
167. Beltowski J. Role of leptin in blood pressure regulation and arterial hypertension // J. Hypertens. - 2006. - Vol. 24, № 5. - P. 789-801.
168.
169. Piatti P., Di Mario C., Monti L.D. et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting // Circulation. - 2003. - Vol. 108, № 17. - P. 2074-2081.
170.
171. Wallerstedt S.M., Eriksson A.L., Niklason A. et al. Serum leptin and myocardial infarction in hypertension // Blood Press. - 2004. - Vol.13, № 4. - P. 243-246.
172.
173. Koh K.K., Quon M.J., Lee S.J. et al. Efonidipine simultaneously improves blood pressure, endothelial function, and metabolic parameters in non-diabetic patients with hypertension // Diabetes Care. - 2007. - Vol. 30, № 6. - P. 1605-1607.
174.
175. Chiba T., Shinozaki S., Nakazawa T. et al. Leptin deficiency suppresses progression of atherosclerosis in apoE-deficient mice // Atherosclerosis - 2008. -Vol. 196, № 1. - P. 68-75.
176.
177. Corsonello A., Perticone F., Malara A. Leptin-dependent platelet aggregation in healthy, overweight and obese subjects // Int. J. Obes. Relat. Metab. Disord. - 2003. - Vol. 27, № 5. - P. 566-573.
178.
179. Zaman A.K., Fujii S., Sawa H. et al. Angiotensin-converting enzyme inhibition attenuates hypofibrinolysis and reduces cardiac perivascular fibrosis in genetically obese diabetic mice // Circulation. - 2001. - Vol. 103, № 25. - P. 3123-3128.
180.
181. Thogersen A.M., Jansson J.H., Boman K. et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor // Circulation. - 1998. - Vol. 98, № 21. - P. 2241-2247.
Для цитирования:
Чумакова Г.А., Веселовская Н.Г., Козаренко А.А., Барбараш Л.С. Локальныежировые депо как фактор риска сердечно-сосудистых заболеваний. Артериальная гипертензия. 2010;16(5):441-448. https://doi.org/10.18705/1607-419X-2010--5-
For citation:
Chumakova G.A., Veselovskaya N.G., Kоzarenko A.A., Barbarash L.S. Local fat depots asa cardiovascular risk factor. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2010;16(5):441-448. (In Russ.) https://doi.org/10.18705/1607-419X-2010--5-
Просмотров: 63
Послать статью по эл. почте 